tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

URGN Stock Latest News

UroGen Pharma’s Earnings Call: Achievements and Challenges
Company AnnouncementsUroGen Pharma’s Earnings Call: Achievements and Challenges
5d ago
URGN
UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
PremiumThe Fly
UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
7d ago
URGN
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
PremiumCompany Announcements
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
10d ago
URGN
Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
PremiumRatings
Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
11d ago
URGN
UroGen Pharma reports Q2 EPS ($1.05), consensus (83c)
PremiumThe Fly
UroGen Pharma reports Q2 EPS ($1.05), consensus (83c)
11d ago
URGN
UroGen Pharma announces 24-month DOR for Phase 3 ENVISION trial
PremiumThe FlyUroGen Pharma announces 24-month DOR for Phase 3 ENVISION trial
13d ago
URGN
UroGen Pharma announces publication of Phase 3b ZUSDURI study results
Premium
The Fly
UroGen Pharma announces publication of Phase 3b ZUSDURI study results
21d ago
URGN
UroGen Pharma announces five-year long-term extension study of ZUSDURI
Premium
The Fly
UroGen Pharma announces five-year long-term extension study of ZUSDURI
28d ago
URGN
UroGen Pharma call volume above normal and directionally bullish
PremiumThe Fly
UroGen Pharma call volume above normal and directionally bullish
1M ago
URGN
UroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA Approvals
PremiumRatings
UroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA Approvals
1M ago
URGN
UroGen Pharma completes enrollment in Phase 3 UTOPIA trial of UGN-103
PremiumThe Fly
UroGen Pharma completes enrollment in Phase 3 UTOPIA trial of UGN-103
1M ago
URGN
UroGen Pharma Approves Bonuses After FDA Approval
PremiumCompany Announcements
UroGen Pharma Approves Bonuses After FDA Approval
2M ago
8K
URGN
Sweetgreen, Urogen, CoreWeave, Allegro, Dexcom: Trending by Analysts
PremiumWeekend UpdatesSweetgreen, Urogen, CoreWeave, Allegro, Dexcom: Trending by Analysts
2M ago
SG
ALGM
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
2M ago
CEP
RDW
UroGen Pharma upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
UroGen Pharma upgraded to Buy from Neutral at H.C. Wainwright
2M ago
URGN
UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
PremiumThe Fly
UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
2M ago
URGN
UroGen Pharma price target raised to $31 from $10 at Oppenheimer
PremiumThe Fly
UroGen Pharma price target raised to $31 from $10 at Oppenheimer
2M ago
URGN
UroGen Pharma price target raised to $47 from $23 at Scotiabank
PremiumThe Fly
UroGen Pharma price target raised to $47 from $23 at Scotiabank
2M ago
URGN
FDA Approves Urogen Pharma’s ZUSDURI for Bladder Cancer
PremiumCompany Announcements
FDA Approves Urogen Pharma’s ZUSDURI for Bladder Cancer
2M ago
8K
URGN
UroGen Pharma price target raised to $30 from $15 at Guggenheim
PremiumThe FlyUroGen Pharma price target raised to $30 from $15 at Guggenheim
2M ago
URGN
UroGen’s Zusduri approval validates FDA’s flexibility, says D. Boral
Premium
The Fly
UroGen’s Zusduri approval validates FDA’s flexibility, says D. Boral
2M ago
URGN
UroGen Pharma trading resumes
Premium
The Fly
UroGen Pharma trading resumes
2M ago
URGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >